Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting

Thrombosis Research

Volumn 134, Issue 1, 2014, Pages 105-110

  Stimpfle, Fabian ^a   Karathanos, Athanasios ^a   Droppa, Michal ^a   Metzger, Janina ^a   Rath, Dominik ^a   Müller, Karin ^a   Tavlaki, Elli ^a   Schäffeler, Elke ^b,c   Winter, Stefan ^b,c   Schwab, Matthias ^a,b   Gawaz, Meinrad ^a   Geisler, Tobias ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Acute coronary syndrome; Clopidogrel; CYP2C19; Pharmacogenetics; Prasugrel; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19; PIPERAZINE DERIVATIVE; PRASUGREL; THIOPHENE DERIVATIVE; TICAGRELOR;

ACUTE CORONARY SYNDROME; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; HOSPITAL INFORMATION SYSTEM; HUMAN; MALE; PILOT STUDY; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; ASPIRIN; CYTOCHROME P-450 CYP2C19; FEMALE; HUMANS; MALE; PILOT PROJECTS; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POINT-OF-CARE SYSTEMS; THIOPHENES;

EID: 84902553307     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.05.006     Document Type: Article

References (34)

1. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 11 2009 1045 1057
2. T. Geisler, E. Elke Schaeffeler, M. Gawaz, and M. Schwab Genetic variation of platelet function and pharmacology:An update of current knowledge Thromb Haemost 110 2 2013
3. C. Davison, S. Macintyre, and G.D. Smith The potential social impact of predictive genetic testing for susceptibility to common chronic diseases: a review and proposed research agenda Sociol Health Illn 16 3 1994 340 371
4. C.T. Johansen, and R.A. Hegele Predictive genetic testing for coronary artery disease Crit Rev Clin Lab Sci 46 5-6 2009 343 360
5. U.A. Meyer, U.M. Zanger, and M. Schwab Omics and drug response Annu Rev Pharmacol Toxicol 53 2013 475 502
6. J.D. Roberts, G.A. Wells, M.R. Le May, M. Labinaz, C. Glover, and M. Froeschl et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial Lancet 379 9827 2012 1705 1711
7. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, and H. Bueno et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 23 2011 2999 3054
8. Task Force on the management of STseamiotESoC, P.G. Steg, S.K. James, D. Atar, L.P. Badano, and C. Blomstrom-Lundqvist et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 20 2012 2569 2619
9. P.R. Sinnaeve, H. Bueno, N. Danchin, J. Sanchez-Covisa, and M. Licour Annemans, et al Contemporary pre-hospital management of ACS patients: results from the EPICOR study, Eur Heart J 33 suppl. 1 2012 314-314
10. T. Geisler, E. Schaeffeler, J. Dippon, S. Winter, V. Buse, and C. Bischofs et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation Pharmacogenomics 9 9 2008 1251 1259
11. K. Muller, S. Aichele, M. Herkommer, B. Bigalke, K. Stellos, and P. Htun et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease Atherosclerosis 213 1 2010 256 262
12. D. Sibbing, S. Braun, S. Jawansky, W. Vogt, J. Mehilli, and A. Schomig et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment Thromb Haemost 99 1 2008 121 126
13. D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, and A. Schomig et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 10 2009 849 856
14. O. Tóth, A. Calatzis, S. Penz, H. Losonczy, and W. Siess Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood Thromb Haemost 96 6 2006 781 788
15. D.S. Streetman, J.S. Bertino Jr., and A.N. Nafziger Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes Pharmacogenetics 10 3 2000 187 216
16. C.S. Zuern, M. Schwab, M. Gawaz, and T. Geisler Platelet pharmacogenomics J Thromb Haemost 8 6 2010 1147 1158
17. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, J.R. Walker, and T. Simon et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 9749 2010 1312 1319
18. J.L. Ferreiro, S. Homs, J. Berdejo, G. Roura, J. Gomez-Lara, and R. Romaguera et al. Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery Thromb Haemost 110 1 2013 110 117
19. M. Frossard, I. Fuchs, J.M. Leitner, K. Hsieh, M. Vlcek, and H. Losert et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction Circulation 110 11 2004 1392 1397
20. I. Fuchs, M. Frossard, A. Spiel, E. Riedmuller, A.N. Laggner, and B. Jilma Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS J Thromb Haemost 4 12 2006 2547 2552
21. G. Sardella, S. Calcagno, M. Mancone, R. Palmirotta, L. Lucisano, and E. Canali et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial Circ Cardiovasc Interv 5 5 2012 698 704
22. U.S. Tantry, K.P. Bliden, C. Wei, R.F. Storey, M. Armstrong, and K. Butler et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies Circ Cardiovasc Genet 3 6 2010 556 566
23. L. Wallentin, S. James, R.F. Storey, M. Armstrong, B.J. Barratt, and J. Horrow et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 9749 2010 1320 1328
24. D. Alexopoulos, A. Galati, I. Xanthopoulou, E. Mavronasiou, G. Kassimis, and K.C. Theodoropoulos et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study J Am Coll Cardiol 60 3 2012 193 199
25. G. Parodi, R. Valenti, B. Bellandi, A. Migliorini, R. Marcucci, and V. Comito et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 15 2013 1601 1606
26. D. Alexopoulos, I. Xanthopoulou, V. Gkizas, G. Kassimis, K.C. Theodoropoulos, and G. Makris et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 6 2012 797 804
27. B. Bigalke, T. Geisler, K. Stellos, H. Langer, K. Daub, and E. Kremmer et al. Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome Am Heart J 156 1 2008 193 200
28. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 23 2003 2908 2913
29. D. Alexopoulos, I. Xanthopoulou, P. Davlouros, G. Tsigkas, A. Damelou, and K.C. Theodoropoulos et al. Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients J Thromb Haemost 11 2 2013 381 384
30. A.L. Frelinger III, A.D. Michelson, S.D. Wiviott, D. Trenk, F.J. Neumann, and D.L. Miller et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44 Thromb Haemost 106 2 2011 219 226
31. T. Cuisset, M. Loosveld, P.E. Morange, J. Quilici, P.J. Moro, and N. Saut et al. CYP2C19*2 and*17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome JACC Cardiovasc Interv 5 12 2012 1280 1287
32. C. Grosdidier, J. Quilici, M. Loosveld, L. Camoin, P.J. Moro, and N. Saut et al. Effect of CYP2C19*2 and*17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications Am J Cardiol 111 7 2013 985 990
33. C.C. Franken, A.F. Kaiser, J.C. Kruger, K. Overbeck, A. Mugge, and H. Neubauer Cytochrome P450 2B6 and 2C9 genotype polymorphism-a possible cause of prasugrel low responsiveness Thromb Haemost 110 1 2013 131 140
34. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 8 2009 849 857